Sarepta stock slides 11% premarket on report FDA was leaning toward rejecting its gene therapy for Duchenne muscular dystrophyMarket Watch • 04/13/23
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023Business Wire • 04/10/23
SRPT LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPTPRNewsWire • 04/06/23
Sarepta Stock Has $30 to $40 Upside if Panel on Gene Therapy Drug Positive, Says AnalystBarrons • 04/04/23
SAREPTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sarepta Therapeutics, Inc. on Behalf of Sarepta Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 03/29/23
SRPT INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPTPRNewsWire • 03/25/23
SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the FirmBusiness Wire • 03/23/23
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) InvestigationBusiness Wire • 03/21/23
Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/21/23
INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPTPRNewsWire • 03/20/23
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPTBusiness Wire • 03/17/23
Sarepta Therapeutics plummets 20% after FDA contradicts company and requires advisory meetingMarket Watch • 03/16/23
Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001Business Wire • 03/16/23